A new vaccine for Ebola showed high efficacy in preventing the development of Ebola in clusters of people exposed to the virus, and protection was also conferred to those who were not vaccinated.
Changes in messenger RNA abundance proved to be a reliable means of predicting patient's chances of surviving Ebola virus disease.
Liberia's Men's Health Screening Program for Ebola survivors successful in spite of complex challenges.
Virus is more likely to be found in male survivors older than 40, researchers report.
The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of a candidate vaccine that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition.
The CDC releases infection control measures implemented at a Texas hospital.
Approximately one-fifth developed severe or total vision loss within weeks of recovery.
Antibody is cost-effective, reducing economic burden that may result from this dangerous virus.
One vaccine provided first as a primer, and the second given as a booster.
Six months after active illness, headaches, memory loss, depression were still being reported.
Most patients received IV fluids and electrolyte supplementation, antibiotics, investigational treatment.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Restricting Fluoroquinolone Use Helped With CDI Decline in England
- Severe CDI Treatment With Vancomycin Has Lower 30-Day Mortality Risk
- Fecal Microbiota Transplant Effective for C Difficile in Pregnancy
- FDA Issues Guidance on Medical Product Marketing Language
- The Handoff: Your Week in Infectious Disease News - 2/17/17